Comparing the severity of long covid and vitamin D levels

2025-06-18T04:30:49Z

Comparing the severity of long covid and vitamin D levels Karn Matangkha Vichit Punyahotra “Long COVID” is a condition where patients continue with persistent symptoms even after they have recovered from the initial COVID-19 infection. These ongoing symptoms might damage various systems in their body. Several risk factors contribute to long-term COVID-19 development, including vitamin and mineral deficiencies. Vitamin D is an important nutrient for maintaining overall health and may be associated with the onset of long COVID. As a result, we studied the prevalence and compared long COVID cases among individuals with varying vitamin D levels. We also examined the relationship between vitamin D levels and the prevalence of eight long-term COVID-19 symptom categories in 170 patients who had previously been infected with the COVID-19 virus and received treatment at Foresta Clinic. This study used a cross-sectional descriptive design, collecting data by using a case record form that included demographic data, eight long COVID symptom categories, and vitamin D levels. The study results indicated a female-to-male ratio of 1.1:1 among the participants, with a mean age of 45.87±8.65 years. Additionally, 62.4% had received three doses of the COVID-19 vaccination. Long COVID was found in 64.7%, with the majority (50.0%) had mild long COVID, followed by 11.2% with moderate long COVID, and 3.5% with severe long COVID. The blood vitamin D level was 41.2% of participants had insufficient, 30.6% were deficiency, and 28.2% had sufficient status. All participants with severe long COVID had vitamin D deficiency, while 73.7% of moderate, 28.2% of mild, and 13.3% without long COVID were deficient with statistical significance (P<0.001). Participants with long COVID symptoms had significantly lower blood vitamin D levels than those without symptoms (p<0.05) across all symptom categories. Multivariable analysis found that vitamin D deficiency was significantly associated with long COVID symptoms at the 0.05 level. Specifically, associations were found for general symptoms (Adj. OR 4.55 [95%CI 1.88, 10.87]), respiratory symptoms (Adj. OR 6.06 [95%CI 2.37, 15.54]), cardiovascular symptoms (Adj. OR 22.63, 95%CI [5.88, 87.14]), neurological symptoms (Adj. OR 16.22 [95%CI 4.81, 54.65]), musculoskeletal symptoms (Adj. OR 13.77 [95%CI 4.54, 41.82]), skin symptoms (Adj. OR 11.28 [95%CI 4.30, 29.57]), psychiatric symptoms (Adj. OR 3.97 [95%CI 1.56, 10.08]), and the overall occurrence of long COVID (Adj. OR 5.80 [95%CI 2.10, 16.13]). Therefore, assessing and maintaining vitamin D levels, vitamin D supplementation, and sunlight exposure in COVID-19 patients can reduce the risk and severity of long-term COVID symptoms. Dissertation (Ph.D.) -- Anti-aging and Regenerative Medicine, School of Anti-Aging and Regenerative Medicine. Mae Fah Luang University, 2024

The efficacy of poly-D, L-lactic acid (PDLLA) biostimulator injection on facial rejuvenation markers improvement of thai middle age

2025-05-07T07:44:02Z

The efficacy of poly-D, L-lactic acid (PDLLA) biostimulator injection on facial rejuvenation markers improvement of thai middle age Chaichana Srituravanich Paisal Rummaneethorn Background: The quality of skin, especially its elasticity, hydration, and texture, diminishes with age, contributing to visible signs of aging. Poly-D, L-lactic acid (PDLLA) has emerged as a biostimulator that can potentially improve facial skin quality through collagen stimulation. Aim: This study aims to assess the efficacy of PDLLA in improving facial rejuvenation markers in early and late middle age groups. Method: A quasi-experimental study was conducted on 30 participants divided into two age groups (early middle age group: 30-45 years and late middle age group: 45-60 years). Each participant received subdermal PDLLA injections over six months, with skin quality measurements taken at baseline, 2, 4, and 6 months using various instruments including sebum level, elasticity, skin hydration, transepidermal water, spot, pore, wrinkle, and texture. The present study also assesses for GAIS score, patients’ satisfaction score and treatment-related side effect. Results: Significant improvements in skin elasticity, wrinkles, pores, transepidermal water loss (TEWL), and skin hydration were observed starting from two months after treatment and monitored for six months, with more pronounced effects in the older age group. No severe adverse effects were reported. Conclusion: PDLLA is an effective and safe biostimulator for enhancing facial skin quality of Thai middle age group. Dissertation (Ph.D.) -- Anti-aging and Regenerative Medicine, School of Anti-Aging and Regenerative Medicine. Mae Fah Luang University, 2024

ดุษฎีนิพนธ์ (Dissertation)

Comparing the severity of long covid and vitamin D levels

The efficacy of poly-D, L-lactic acid (PDLLA) biostimulator injection on facial rejuvenation markers improvement of thai middle age